S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

IRadimed Stock Forecast, Price & News

+0.49 (+1.10%)
(As of 11/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
119,214 shs
Average Volume
33,471 shs
Market Capitalization
$555.39 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive IRMD News and Ratings via Email

Sign-up to receive the latest news and ratings for IRadimed and its competitors with MarketBeat's FREE daily newsletter.

IRadimed logo

About IRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging (MRI) compatible medical devices. It also provides non-magnetic Intravenous (IV) infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.


See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$31.72 million
Cash Flow
$0.23 per share
Book Value
$5.00 per share


Net Income
$1.37 million
Pretax Margin




Free Float
Market Cap
$555.39 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.03 out of 5 stars

Medical Sector

580th out of 1,390 stocks

Surgical & Medical Instruments Industry

61st out of 127 stocks

Analyst Opinion: 1.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.9 5 -4 -3 -2 -1 -

IRadimed (NASDAQ:IRMD) Frequently Asked Questions

Is IRadimed a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IRadimed in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRadimed stock.
View analyst ratings for IRadimed
or view top-rated stocks.

How has IRadimed's stock price been impacted by COVID-19?

IRadimed's stock was trading at $22.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IRMD shares have increased by 99.9% and is now trading at $45.00.
View which stocks have been most impacted by COVID-19

Are investors shorting IRadimed?

IRadimed saw a decrease in short interest in November. As of November 15th, there was short interest totaling 66,000 shares, a decrease of 33.7% from the October 31st total of 99,500 shares. Based on an average daily trading volume, of 35,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 1.0% of the shares of the company are short sold.
View IRadimed's Short Interest

When is IRadimed's next earnings date?

IRadimed is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for IRadimed

How were IRadimed's earnings last quarter?

IRadimed Co. (NASDAQ:IRMD) posted its earnings results on Thursday, October, 28th. The medical equipment provider reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.17 by $0.06. IRadimed had a trailing twelve-month return on equity of 9.44% and a net margin of 15.77%. During the same period last year, the firm posted $0.09 EPS.
View IRadimed's earnings history

What guidance has IRadimed issued on next quarter's earnings?

IRadimed updated its FY 2021 earnings guidance on Friday, November, 5th. The company provided earnings per share (EPS) guidance of $0.700-$0.710 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.620. The company issued revenue guidance of $41.40 million-$41.60 million, compared to the consensus revenue estimate of $40.16 million.

What price target have analysts set for IRMD?

1 Wall Street analysts have issued 1-year target prices for IRadimed's shares. Their forecasts range from $42.00 to $42.00. On average, they expect IRadimed's share price to reach $42.00 in the next year. This suggests that the stock has a possible downside of 6.7%.
View analysts' price targets for IRadimed
or view top-rated stocks among Wall Street analysts.

Who are IRadimed's key executives?

IRadimed's management team includes the following people:
  • Roger Susi, Chairman, President & Chief Executive Officer
  • Christopher K. Scott, Secretary, Chief Operating & Financial Officer
  • Chris Williamson, Vice President-Information Technology
  • Lynn Neuhardt, Vice President-Research & Development
  • MaryBeth Smith, Vice President-Worldwide Sales

What other stocks do shareholders of IRadimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRadimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).

What is IRadimed's stock symbol?

IRadimed trades on the NASDAQ under the ticker symbol "IRMD."

Who are IRadimed's major shareholders?

IRadimed's stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (5.69%), BlackRock Inc. (3.38%), Russell Investments Group Ltd. (1.51%), Mondrian Investment Partners LTD (1.11%), Rice Hall James & Associates LLC (0.98%) and Geode Capital Management LLC (0.82%). Company insiders that own IRadimed stock include Anthony Vuoto, Brent Johnson, Christopher K Scott, James B Hawkins, Louis S Waldman, Monty K Allen, Monty K Allen and Roger E Susi.
View institutional ownership trends for IRadimed

Which major investors are selling IRadimed stock?

IRMD stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Mondrian Investment Partners LTD, Russell Investments Group Ltd., Foundry Partners LLC, California State Teachers Retirement System, Nisa Investment Advisors LLC, Los Angeles Capital Management LLC, and LPL Financial LLC. Company insiders that have sold IRadimed company stock in the last year include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, and Roger E Susi.
View insider buying and selling activity for IRadimed
or view top insider-selling stocks.

Which major investors are buying IRadimed stock?

IRMD stock was acquired by a variety of institutional investors in the last quarter, including Hillsdale Investment Management Inc., Bares Capital Management Inc., EAM Investors LLC, Dimensional Fund Advisors LP, Two Sigma Advisers LP, Two Sigma Investments LP, BlackRock Inc., and Millennium Management LLC.
View insider buying and selling activity for IRadimed
or or view top insider-buying stocks.

How do I buy shares of IRadimed?

Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IRadimed's stock price today?

One share of IRMD stock can currently be purchased for approximately $45.00.

How much money does IRadimed make?

IRadimed has a market capitalization of $555.39 million and generates $31.72 million in revenue each year. The medical equipment provider earns $1.37 million in net income (profit) each year or $0.48 on an earnings per share basis.

How many employees does IRadimed have?

IRadimed employs 110 workers across the globe.

What is IRadimed's official website?

The official website for IRadimed is www.iradimed.com.

Where are IRadimed's headquarters?

IRadimed is headquartered at 1025 Willa Springs Dr., Winter Springs FL, 32708.

How can I contact IRadimed?

IRadimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at (407) 677-8022, via email at [email protected], or via fax at 407-677-5037.

This page was last updated on 12/1/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.